Marinomed Biotech AG Reports Strong Q1 2025 Financial Results

Marinomed Biotech AG (VSE:MARI) announced a notable increase in revenues for the first quarter of 2025, achieving EUR 6.5 million, a significant rise from EUR 0.7 million in Q1 2024. This growth is largely attributed to the EUR 5.0 million first payment from the sale of the Carragelose business. The operating result reached a positive EUR 22.2 million, reflecting a restructuring gain of EUR 18.9 million.

The company's cash position improved to EUR 4.5 million despite ongoing cyber fraud investigations. CEO Andreas Grassauer highlighted the successful restructuring and sale of Carragelose as pivotal achievements. CFO Gabriele Ram affirmed the company's stability and confidence in receiving earnout payments of up to EUR 15 million on schedule. Marinomed remains committed to advancing its Marinosolv platform and Solv4U business.